Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...

Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...

Chicago-based Northwestern Medicine has built one of the country’s most ambitious transplant programs. Whether performing the first double lung-liver transplant in the U.S., eliminating all traces of ...

Onctura, a clinical-stage biopharmaceutical company developing precision oral small molecules for neglected and hard-to-treat ...

The American College of Medial Genetics and Genomics (ACMG) announced today that press registration is now open for the 2026 ...

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.

Breast cancer can spread—or metastasize—to many different parts of the body, but it's not well understood why tumors grow better in some organs than others.

Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...

Regular walking during recovery may reduce cancer-related fatigue and improve long-term well-being for patients with ...